tailieunhanh - Báo cáo y học: "Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. | Ducourau et al. Arthritis Research Therapy 2011 13 R105 http content 13 3 R105 RESEARCH ARTICLE Open Access Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases Emilie Ducourau1 2t Denis Mulleman1 2 f Gilles Paintaud1 3 Delphine Chu Miow Lin1 2 Francine Lauferon1 2 David Ternant1 3 Hervé Watier1 4 and Philippe Goupille1 2 Abstract Introduction A proportion of patients receiving infliximab have antibodies toward infliximab ATI which are associated with increased risk of infusion reaction and reduced response to treatment. We studied the association of infliximab concentration at treatment initiation and development of ATI as well as the association of the presence of ATI and maintenance of infliximab. Methods All patients with rheumatoid arthritis RA or spondyloarthritis SpA receiving infliximab beginning in December 2005 were retrospectively followed until January 2009 or until infliximab discontinuation. Trough serum infliximab and ATI concentrations were measured at each visit. The patients were separated into two groups ATIpos if ATI were detected at least once during the follow-up period and ATIneg otherwise. Repeated measures analysis of variance was used to study the association of infliximab concentration at treatment initiation and the development of ATI. Maintenance of infliximab in the two groups was studied by using Kaplan-Meier curves. Results We included 108 patients 17 with RA and 91 with SpA. ATI were detected in 21 patients 19 . The median time to ATI detection after initiation of infliximab was months to months . For both RA and SpA patients trough infliximab concentration during the initiation period was significantly lower for ATIpos than ATIneg patients. RA patients showed maintenance of infliximab at a median of months to months and months to months for ATIneg and ATIpos groups .